Shares of Vivus (VVUS) move up 4.2% in premarket trading as the dust still clears from a FDA panel that had implications for weight-loss drug Qnexa. Yesterday's roller coaster ride for VVUS may have been a bit of a case of "itchy trader fingers" with the final word on FDA approval for Qnexa still up in the air.
Vivus (VVUS) has resistance level is $23.75 and support level is $19.55.
More Stocks News
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/